Comparing Chemotherapy Regimens for Advanced Breast Cancer
Author Information
Author(s): T.J. Powles, A.L. Jones, I.R. Judson, J.R. Hardy, S.E. Ashley
Primary Institution: Royal Marsden Hospital
Hypothesis
Is the 3M chemotherapy regimen as effective as the VAC regimen for treating advanced breast cancer?
Conclusion
The 3M regimen is as effective as the VAC regimen but has significantly less symptomatic toxicity.
Supporting Evidence
- The overall response rate for 3M was 53% and for VAC was 49%.
- Symptomatic toxicity was significantly less for 3M compared to VAC.
- There was no significant difference in the duration of response or survival between the two regimens.
- Patients receiving 3M experienced significantly less nausea and vomiting.
Takeaway
Doctors tested two types of chemotherapy for breast cancer to see which worked better. They found that one type worked just as well but made patients feel less sick.
Methodology
A randomized clinical trial comparing two chemotherapy regimens in patients with advanced breast cancer.
Limitations
Patients were not excluded based on adverse survival features, which may affect the generalizability of the results.
Participant Demographics
Median age was 55 years for 3M and 58 years for VAC; most patients had received prior endocrine therapy.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CL 43-62% for 3M and 95% CL 39-58% for VAC
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website